<abstract xmlns="http://www.w3.org/1999/xhtml"><sec id="j_1905-7415.0903.408_s_001_w2aab3b7c14b1b6b1aab1c16b1Aa"><h3>Background</h3><p>Antihistamines are used to treat allergic rhinitis. Whether better pharmacokinetic and pharmacodynamic properties confer higher clinical effectiveness is not known.</p></sec><sec id="j_1905-7415.0903.408_s_002_w2aab3b7c14b1b6b1aab1c16b2Aa"><h3>Objectives</h3><p>To compare the effectiveness of original fexofenadine, original levocetirizine, and locally-manufactured fexofenadine for treating persistent allergic rhinitis.</p></sec><sec id="j_1905-7415.0903.408_s_003_w2aab3b7c14b1b6b1aab1c16b3Aa"><h3>Methods</h3><p>Patients with persistent allergic rhinitis were enrolled during June 2010 to December 2013. Patients were allocated to receive original fexofenadine, original levocetirizine, or locally-manufactured fexofenadine for one week. Daily symptoms were self-assessed. Disease specific quality of life, allergen induced wheal and flare size, peak nasal inspiratory flow, and any adverse events were reported at one week.</p></sec><sec id="j_1905-7415.0903.408_s_004_w2aab3b7c14b1b6b1aab1c16b4Aa"><h3>Results</h3><p>We enrolled 69 patients. There was no significant difference in reduction of mean total symptom score between original fexofenadine, original levocetirizine, and locally-manufactured fexofenadine (mean (95% CI); 5.52 (3.98, 7.06), 4.32 (2.43, 6.21), 4.45 (2.51, 6.40)) respectively. Improvement in otolaryngic symptoms (<italic>P</italic> = 0.51), nonotolaryngic symptoms (<italic>P</italic> = 0.59), work and study performance (<italic>P</italic> = 0.42), exertion (<italic>P</italic> =0.81), sleep disturbance (<italic>P</italic> = 0.76), social disturbance (<italic>P</italic> = 0.16), emotional disturbance (<italic>P</italic> = 0.66), overall general health (<italic>P</italic> =0.55), allergen induced wheal (<italic>P</italic> = 0.44) and flare suppression (<italic>P</italic> = 0.90), and peak nasal inspiratory flow (<italic>P</italic> =0.85) were not significantly different between the 3 groups. All groups similarly reported minor adverse events.</p></sec><sec id="j_1905-7415.0903.408_s_005_w2aab3b7c14b1b6b1aab1c16b5Aa"><h3>Conclusions</h3><p>There is no difference in effectiveness between fexofenadine and levocetirizine in treating persistent allergic rhinitis. Locally-manufactured and original fexofenadine similarly improve symptoms, nasal air flow, and quality of life. No major drug-related adverse events were reported.</p></sec></abstract>

BackgroundAntihistamines are used to treat allergic rhinitis. Whether better pharmacokinetic and pharmacodynamic properties confer higher clinical effectiveness is not known.ObjectivesTo compare the effectiveness of original fexofenadine, original levocetirizine, and locally-manufactured fexofenadine for treating persistent allergic rhinitis.MethodsPatients with persistent allergic rhinitis were enrolled during June 2010 to December 2013. Patients were allocated to receive original fexofenadine, original levocetirizine, or locally-manufactured fexofenadine for one week. Daily symptoms were self-assessed. Disease specific quality of life, allergen induced wheal and flare size, peak nasal inspiratory flow, and any adverse events were reported at one week.ResultsWe enrolled 69 patients. There was no significant difference in reduction of mean total symptom score between original fexofenadine, original levocetirizine, and locally-manufactured fexofenadine (mean (95% CI); 5.52 (3.98, 7.06), 4.32 (2.43, 6.21), 4.45 (2.51, 6.40)) respectively. Improvement in otolaryngic symptoms (P = 0.51), nonotolaryngic symptoms (P = 0.59), work and study performance (P = 0.42), exertion (P =0.81), sleep disturbance (P = 0.76), social disturbance (P = 0.16), emotional disturbance (P = 0.66), overall general health (P =0.55), allergen induced wheal (P = 0.44) and flare suppression (P = 0.90), and peak nasal inspiratory flow (P =0.85) were not significantly different between the 3 groups. All groups similarly reported minor adverse events.ConclusionsThere is no difference in effectiveness between fexofenadine and levocetirizine in treating persistent allergic rhinitis. Locally-manufactured and original fexofenadine similarly improve symptoms, nasal air flow, and quality of life. No major drug-related adverse events were reported.

Fexofenadine and levocetirizine have equivalent effectiveness for persistent allergic rhinitis

Department of Otolaryngology, Faculty of Medicine

Asian Biomedicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

BackgroundAntihistamines are used to treat allergic rhinitis. Whether better pharmacokinetic and pharmacodynamic properties confer higher clinical...

Fexofenadine and levocetirizine have equivalent effectiveness for persistent allergic rhinitis

Article Category: Brief communication (Original)

Online veröffentlicht: 31. Jan. 2017

Seitenbereich: 387 - 395

DOI: https://doi.org/10.5372/1905-7415.0903.408

Schlüsselwörter
allergic rhinitis, H antagonists, antihistamines, fexofenadine, levocetirizine, local-manufactured drugs, generic

© 2015 Kornkiat Snidvongs, Chutima Rotjanasiriphong, Chantima Phannaso, Supinda Chusakul, Songklot Aeumjaturapat

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Fexofenadine and levocetirizine have equivalent effectiveness for persistent allergic rhinitis

Article Category: Brief communication (Original)

Online veröffentlicht: 31. Jan. 2017

Seitenbereich: 387 - 395

DOI: https://doi.org/10.5372/1905-7415.0903.408

Schlüsselwörterallergic rhinitis, H antagonists, antihistamines, fexofenadine, levocetirizine, local-manufactured drugs, generic

© 2015 Kornkiat Snidvongs, Chutima Rotjanasiriphong, Chantima Phannaso, Supinda Chusakul, Songklot Aeumjaturapat

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Schlüsselwörter
allergic rhinitis, H antagonists, antihistamines, fexofenadine, levocetirizine, local-manufactured drugs, generic